End-stage renal disease (ESRD) affects almost 350,000 people living in the United States with an incidence that has increased by over 50 percent in the past decade. The two current treatment modalities for ESRD, dialysis and transplantation, both have significant limitations. Patients on dialysis have an extremely high mortality rate, approaching 20 percent per year. Although patient survival is markedly improved with renal transplantation, the number of renal transplants is severely limited by the short supply of available organs and many patients die while awaiting transplantation of a kidney allograft. Recently, several alternative modalities have been proposed including augmentation of traditional hemodialysis with a "renal assist device," xenotranplantation of whole developing kidney rudiments into adults, and the generation of histocompatible renal tissue using nuclear transplantation techniques.
Scientists at UC San Diego have developed a method of propagating ureteric bud (UB) cells in culture under conditions that induce the UB to undergo branching morphogenesis in order to generate a population of UB comprising tubular branches, subdividing the UB population, and resuspending each subpopulation in culture media. They have isolated an epithelial ureteric bud branching morphogenetic activity from the metanephric mesenchyme-derived cell conditioned medium and identified one of such molecules as an 18 kDa heparin binding protein, pleiotrophin. The invention demonstrates that purified pleiotrophin induces impressive branching morphogenesis of the isolated UB in vitro and provides methods of using pleiotrophin and compositions comprising pleiotrophin or other factors in the conditioned medium to induce morphogenesis in the kidney cells in vitro and in vivo. Additionally, methods and compositions are provided for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue and treating renal failure.
Potential uses of pleiotrophin and related factors include:
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 8,148,149 | 04/03/2012 | 2001-205 |
United States Of America | Issued Patent | 7,326,570 | 02/05/2008 | 2001-205 |